Dynamic Technology Lab Private Ltd Takes $238,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Dynamic Technology Lab Private Ltd purchased a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 19,894 shares of the company’s stock, valued at approximately $238,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in shares of Olema Pharmaceuticals by 67.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock valued at $132,000 after purchasing an additional 4,442 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Olema Pharmaceuticals in the 2nd quarter valued at $145,000. SG Americas Securities LLC acquired a new position in Olema Pharmaceuticals in the 3rd quarter valued at $156,000. Ensign Peak Advisors Inc raised its position in Olema Pharmaceuticals by 6.1% during the 2nd quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company’s stock worth $161,000 after buying an additional 850 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Olema Pharmaceuticals in the 3rd quarter worth $163,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OLMA. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. reduced their price target on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $27.00.

Olema Pharmaceuticals Stock Performance

OLMA stock opened at $10.12 on Monday. The company’s 50-day moving average price is $11.30 and its 200 day moving average price is $11.90. Olema Pharmaceuticals, Inc. has a 52 week low of $7.68 and a 52 week high of $16.77. The company has a market cap of $579.86 million, a P/E ratio of -4.62 and a beta of 2.02.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.